BioAegis Therapeutics develops novel protein replacement therapies targeted at saving lives based on the endogenous human protein, plasma gelsolin (pGSN).
8 0% Last mo
4 years ago
Use BioAegis Therapeutics's historical employee count to better understand their growth and spending over time.
Unlock with a Free Trial
Use BioAegis Therapeutics's historical monthly uniques as a proxy for mindshare and web traction.
Use BioAegis Therapeutics's historical Twitter followers and likes to better understand their social media traction over time.
Use BioAegis Therapeutics's historical Linkedin followers to better understand their social media traction over time.
Use BioAegis Therapeutics's mobile downloads and app ranks to evaluate the performance of their mobile apps.
BioAegis Therapeutics Announces Addition of Leading Critical Care Nephrologist to its Clinical Advisory Board
BioAegis Therapeutics and TH Chan Harvard School of Public Health Awarded 3-Year $2.8MM NIH Grant to Study Plasma Gelsolin Immunotherapy to Limit Antibiotic-Resistant Pneumonia
BioAegis Therapeutics Nets VC Equity